Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-12-29
- Target Recruit Count
- 25
- Registration Number
- NCT05343325
- Locations
- 🇨🇳
Zhigang Liu, Dongguan, China
🇨🇳Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT05339581
- Locations
- 🇨🇳
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05319639
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 46
- Registration Number
- NCT05319574
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT05314101
- Locations
- 🇨🇳
FujianCH, Fuzhou, Fujian, China
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05303090
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05303844
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-03-22
- Target Recruit Count
- 20
- Registration Number
- NCT05291052
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-07-13
- Target Recruit Count
- 30
- Registration Number
- NCT05273814
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 53
- Registration Number
- NCT05267054
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.